Acadia Pharmaceuticals
ACAD
ACAD
231 hedge funds and large institutions have $5.28B invested in Acadia Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 62 funds opening new positions, 74 increasing their positions, 66 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
12% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 66
1.45% more ownership
Funds ownership: 95.87% → 97.32% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Holders
231
Holding in Top 10
3
Calls
$79.5M
Puts
$52.7M
Top Buyers
| 1 | +$95M | |
| 2 | +$56.2M | |
| 3 | +$40.4M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.2M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$24.9M |
Top Sellers
| 1 | -$60.8M | |
| 2 | -$42.8M | |
| 3 | -$20M | |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$15.7M |
| 5 |
Goldman Sachs
New York
|
-$13.6M |